HK1138502A1 - Combination of blys inhibition and/or april inhibition and immunosuppressants for treatment of autoimmune disease - Google Patents
Combination of blys inhibition and/or april inhibition and immunosuppressants for treatment of autoimmune diseaseInfo
- Publication number
- HK1138502A1 HK1138502A1 HK10103878.9A HK10103878A HK1138502A1 HK 1138502 A1 HK1138502 A1 HK 1138502A1 HK 10103878 A HK10103878 A HK 10103878A HK 1138502 A1 HK1138502 A1 HK 1138502A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- blys
- inhibition
- fusion protein
- april
- immunosuppressants
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90836507P | 2007-03-27 | 2007-03-27 | |
PCT/US2008/058486 WO2008119042A2 (en) | 2007-03-27 | 2008-03-27 | Combination of blys inhibition and/or april inhibition and immunnosuppressants for treatment of autoimmune disease |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1138502A1 true HK1138502A1 (en) | 2010-08-27 |
Family
ID=39789276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10103878.9A HK1138502A1 (en) | 2007-03-27 | 2010-04-21 | Combination of blys inhibition and/or april inhibition and immunosuppressants for treatment of autoimmune disease |
Country Status (19)
Country | Link |
---|---|
US (2) | US8852591B2 (xx) |
EP (1) | EP2139517B1 (xx) |
JP (1) | JP5426531B2 (xx) |
CN (1) | CN101678106B (xx) |
AU (1) | AU2008230777B8 (xx) |
CA (1) | CA2681728C (xx) |
DK (1) | DK2139517T3 (xx) |
EA (1) | EA030313B1 (xx) |
ES (1) | ES2422479T3 (xx) |
HK (1) | HK1138502A1 (xx) |
HR (1) | HRP20130725T1 (xx) |
IL (1) | IL201114A (xx) |
MX (1) | MX2009010125A (xx) |
PL (1) | PL2139517T3 (xx) |
PT (1) | PT2139517E (xx) |
RS (1) | RS52888B (xx) |
SI (1) | SI2139517T1 (xx) |
WO (1) | WO2008119042A2 (xx) |
ZA (1) | ZA200906808B (xx) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8212004B2 (en) * | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
US6812327B1 (en) * | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
WO2002002641A1 (en) * | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
EA015860B1 (ru) * | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
WO2007123765A2 (en) * | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
EP2396035A4 (en) * | 2009-02-12 | 2012-09-12 | Human Genome Sciences Inc | USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE |
US20130028897A1 (en) * | 2009-04-27 | 2013-01-31 | Ali Naji | Methods for reducing the level of alloantibodies in a subject |
EA201290837A1 (ru) * | 2010-03-03 | 2013-05-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение волчаночного нефрита с применением лаквинимода |
CN101851278B (zh) * | 2010-05-26 | 2013-03-13 | 石药集团中奇制药技术(石家庄)有限公司 | B细胞激活因子拮抗剂及其制备方法与用途 |
US10017762B2 (en) | 2010-11-24 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for treating or preventing lupus |
US9657292B2 (en) | 2010-11-24 | 2017-05-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for treating or preventing lupus |
CN102085367B (zh) * | 2011-01-19 | 2012-08-22 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白用于制备治疗类风湿性关节炎药物的应用 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
CN103169966B (zh) * | 2013-04-09 | 2015-04-01 | 中国人民解放军军事医学科学院基础医学研究所 | 一种治疗系统性红斑狼疮的药物组合物 |
NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
CA2945486A1 (en) | 2014-02-07 | 2015-08-13 | Mcmaster University | Trifunctional t cell-antigen coupler and methods and uses thereof |
CN103965295B (zh) * | 2014-04-18 | 2015-12-02 | 天津大学 | BLyS拮抗肽、含TA-Fc融合蛋白基因的质粒及TA-Fc融合蛋白 |
CN103936833B (zh) * | 2014-04-18 | 2016-02-10 | 天津大学 | BLyS拮抗肽、含TC-Fc融合蛋白基因的质粒及TC-Fc融合蛋白 |
US10562954B2 (en) * | 2014-05-12 | 2020-02-18 | Shanghai Kanda Biotechnology Co., Ltd. | Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof |
SI3380522T1 (sl) | 2015-11-25 | 2024-02-29 | Visterra, Inc. | Molekule protitelesa proti APRIL in uporabe le-teh |
EP3483181A4 (en) * | 2016-07-06 | 2020-04-22 | Shanghai Pharmaexplorer Co., Ltd. | BLYS ANTIBODIES, PRODUCTION METHOD THEREFOR AND APPLICATION THEREOF |
CA3078637A1 (en) | 2017-10-12 | 2019-04-18 | Mcmaster University | T cell-antigen coupler with y182t mutation and methods and uses thereof |
US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
CA3086661C (en) * | 2018-08-30 | 2022-04-12 | The Governing Council Of The University Of Toronto | Methods of treating an autoimmune disease |
US20210401939A1 (en) * | 2018-11-21 | 2021-12-30 | The Governing Council Of The University Of Toronto | Methods of treating an autoimmune disease |
WO2020210670A1 (en) * | 2019-04-12 | 2020-10-15 | Biograph 55, Inc. | Compositions and methods for cancer immunotherapy |
US20230144779A1 (en) * | 2019-12-20 | 2023-05-11 | Vyome Therapeutics Inc. | Formulations and method for treatment of inflammatory diseases |
KR20220034742A (ko) * | 2019-12-24 | 2022-03-18 | 레메젠 코, 리미티드 | Taci-fc 융합 단백질 및 그 용도 |
PE20230494A1 (es) | 2020-05-08 | 2023-03-23 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas |
WO2021243298A1 (en) * | 2020-05-29 | 2021-12-02 | Chinook Therapeutics, Inc. | Methods of treating iga nephropathy with an april binding antibody |
WO2021247512A1 (en) * | 2020-06-02 | 2021-12-09 | Merck Patent Gmbh | Methods related to the treatment of iga nephropathy |
US12016923B2 (en) | 2021-06-01 | 2024-06-25 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 T cell-antigen couplers and uses thereof |
US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
JP2024510636A (ja) * | 2021-08-10 | 2024-03-08 | レメゲン シーオー.,エルティーディー. | TACI-Fc融合タンパク質を用いたIgA腎症の治療方法 |
KR20240053675A (ko) * | 2021-08-11 | 2024-04-24 | 악소 바이오파마슈티컬 인코포레이티드 | sBCMA 변이체 및 이의 FC 융합 단백질을 이용한 IgA, IgM 및/또는 IgG의 생산 감소 방법 |
CA3236667A1 (en) * | 2022-06-08 | 2023-12-14 | Jianmin Fang | Method for treating myasthenia gravis with taci-fc fusion protein |
WO2024159715A1 (zh) * | 2023-01-31 | 2024-08-08 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗IgG4相关性疾病的方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006201471B2 (en) * | 2000-02-16 | 2009-07-23 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of TNF-related molecules |
IL150755A0 (en) * | 2000-02-16 | 2003-02-12 | Genentech Inc | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
KR101021124B1 (ko) * | 2001-05-24 | 2011-03-14 | 지모제넥틱스, 인코포레이티드 | Taci-면역글로불린 융합 단백질 |
AU2002322301A1 (en) * | 2001-06-26 | 2003-03-03 | Gene Logic, Inc. | Methods for the diagnosis and treatment of cardiac tissue rejection |
HUP0500992A3 (en) * | 2001-08-03 | 2007-11-28 | Genentech Inc | Tacis and br3 polypeptides and uses thereof |
CA2467521A1 (en) * | 2001-11-16 | 2003-07-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
US20080181886A1 (en) * | 2004-11-04 | 2008-07-31 | Genentech, Inc. | Polypeptides That Bind Baff And/Or April |
BRPI0518432A2 (pt) | 2004-11-17 | 2008-11-25 | Angiogen Pharmaceuticals Pty L | mÉtodo de modular o funcionamento de cÉlula b |
AU2006281978A1 (en) * | 2005-08-12 | 2007-02-22 | Garvan Institute Of Medical Research | Phrophylactic and/or therapeutic method for treatment of autoimmune disease |
BRPI0711823A2 (pt) * | 2006-05-15 | 2012-01-17 | Ares Trading Sa | métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig |
EP2219675B1 (en) | 2007-11-12 | 2013-10-23 | Ares Trading S.A. | Formulations for taci-immunoglobulin fusion proteins |
-
2008
- 2008-03-27 PT PT87444873T patent/PT2139517E/pt unknown
- 2008-03-27 CA CA2681728A patent/CA2681728C/en active Active
- 2008-03-27 RS RS20130268A patent/RS52888B/en unknown
- 2008-03-27 AU AU2008230777A patent/AU2008230777B8/en active Active
- 2008-03-27 MX MX2009010125A patent/MX2009010125A/es active IP Right Grant
- 2008-03-27 EP EP08744487.3A patent/EP2139517B1/en active Active
- 2008-03-27 ES ES08744487T patent/ES2422479T3/es active Active
- 2008-03-27 PL PL08744487T patent/PL2139517T3/pl unknown
- 2008-03-27 WO PCT/US2008/058486 patent/WO2008119042A2/en active Application Filing
- 2008-03-27 US US12/057,133 patent/US8852591B2/en active Active
- 2008-03-27 DK DK08744487.3T patent/DK2139517T3/da active
- 2008-03-27 EA EA200901213A patent/EA030313B1/ru not_active IP Right Cessation
- 2008-03-27 JP JP2010501224A patent/JP5426531B2/ja active Active
- 2008-03-27 CN CN2008800155908A patent/CN101678106B/zh active Active
- 2008-03-27 SI SI200831015T patent/SI2139517T1/sl unknown
-
2009
- 2009-09-23 IL IL201114A patent/IL201114A/en active IP Right Grant
- 2009-09-30 ZA ZA2009/06808A patent/ZA200906808B/en unknown
-
2010
- 2010-04-21 HK HK10103878.9A patent/HK1138502A1/xx unknown
-
2013
- 2013-08-01 HR HRP20130725AT patent/HRP20130725T1/hr unknown
-
2014
- 2014-08-18 US US14/461,885 patent/US20150017164A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2008230777B8 (en) | 2014-07-03 |
IL201114A (en) | 2014-01-30 |
CA2681728C (en) | 2015-12-22 |
CN101678106B (zh) | 2013-06-05 |
ZA200906808B (en) | 2011-10-26 |
JP5426531B2 (ja) | 2014-02-26 |
AU2008230777B2 (en) | 2014-02-27 |
MX2009010125A (es) | 2010-02-17 |
US20150017164A1 (en) | 2015-01-15 |
CN101678106A (zh) | 2010-03-24 |
ES2422479T3 (es) | 2013-09-11 |
WO2008119042A3 (en) | 2009-04-30 |
EP2139517B1 (en) | 2013-05-29 |
EA030313B1 (ru) | 2018-07-31 |
CA2681728A1 (en) | 2008-10-02 |
DK2139517T3 (da) | 2013-08-26 |
HRP20130725T1 (xx) | 2013-10-11 |
RS52888B (en) | 2014-02-28 |
EP2139517A2 (en) | 2010-01-06 |
AU2008230777A1 (en) | 2008-10-02 |
SI2139517T1 (sl) | 2013-09-30 |
IL201114A0 (en) | 2010-05-17 |
US20080260737A1 (en) | 2008-10-23 |
EA200901213A1 (ru) | 2010-04-30 |
PL2139517T3 (pl) | 2013-10-31 |
US8852591B2 (en) | 2014-10-07 |
WO2008119042A2 (en) | 2008-10-02 |
PT2139517E (pt) | 2013-07-11 |
AU2008230777A8 (en) | 2014-07-03 |
JP2010522767A (ja) | 2010-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1138502A1 (en) | Combination of blys inhibition and/or april inhibition and immunosuppressants for treatment of autoimmune disease | |
WO2008064321A3 (en) | Methods of treating chronic inflammatory diseases using a gm-csf antagonist | |
EA200701370A1 (ru) | Способы получения стерильных суспензий или лиофилизатов труднорастворимых комплексов основных пептидов (варианты), стерильная суспензия и лиофилизат вышеназванных комплексов, фармацевтическая композиция, набор и лекарственное средство на их основе | |
WO2007027761A3 (en) | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease | |
HUE046110T2 (hu) | Gyógyászati készítmények a rheumatoid arthritis betegségének és tüneteinek kezelésére | |
EP3552607A3 (en) | Imidazopyrazine syk inhibitors | |
EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
WO2006036729A3 (en) | USE OF TGF-β ANTAGONISTS TO LIMIT NEPHROTOXICITY OF IMMUNOSUPPRESSIVE AGENTS | |
Ferro et al. | Cyclo‐Gly‐Pro, a cyclic dipeptide, attenuates nociceptive behaviour and inflammatory response in mice | |
Serata et al. | Are 5‐HT3 antagonists effective in obsessive–compulsive disorder? A systematic review of literature | |
WO2007096396A3 (en) | Methods for treating autoimmune or demyelinating diseases | |
MA30865B1 (fr) | Utilisation de cyclosporines modifiees | |
WO2007034490A3 (en) | Diastereomeric peptides for modulating t cell immunity | |
Segarra Medrano et al. | Efficacy and safety of combined cyclosporin A and mycophenolate mofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis | |
Pelayo et al. | Localisation and activation of the neurokinin 1 receptor in the enteric nervous system of the mouse distal colon | |
Srivastava et al. | Current Update on Evidence based Literature ofTofisopam | |
HK1072012A1 (en) | 5-ht4 receptor antagonists for the treatment of heart failure | |
Stenberg et al. | Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia–a path model investigation | |
MA32129B1 (fr) | Cyclosporine non immunosuppressive pour le traitement de la dystrophie musculaire | |
Smyth et al. | Coincident membranous glomerulonephritis and chronic inflammatory demyelinating polyradiculoneuropathy: questioning the autoimmunity hypothesis | |
Huang et al. | Taiwan Dementia Treatment Guideline. | |
CY1114268T1 (el) | Συνδυασμος αναστολης blys και μυκοφαινολικης μοφετιλης για θεραπεια αυτοανοσης ασθενειας | |
Koh et al. | Early aggressive immunotherapy improves functional outcome in chronic immune sensory polyradiculopathy | |
EA200802354A1 (ru) | Средство и способ повышения половой активности человека | |
US8557959B2 (en) | Allele and isotope-specific intervention on MHC class II molecules associated with autoimmune diseases by means of peptides |